Grifols (GRFS) Inventory Average (2011 - 2025)
Grifols (GRFS) reported Inventory Average of $3.8 billion for Q4 2025, up 108.15% on a YoY basis from $1.8 billion in Q4 2024, and up 108.15% quarter-over-quarter from $1.8 billion in Q4 2024.
Grifols (GRFS) Inventory Average (2011 - 2025) Analysis & Trends
Grifols has reported Inventory Average for 15 years, with the latest figure at $3.8 billion in Q4 2025.
- For the quarter ending Q4 2025, Inventory Average rose 108.15% year-over-year to $3.8 billion; the trailing twelve-month figure through Dec 2025 stood at $3.8 billion (up 108.15% YoY), and the FY2025 full-year result was $3.8 billion, up 108.15% from the prior year.
- Inventory Average for Q4 2025 stood at $3.8 billion, up from $1.8 billion in the prior quarter.
- The five-year high for Inventory Average was $3.8 billion in Q4 2025, with the low at -$163.9 million in Q4 2021.
- Historically, Inventory Average has averaged $1.0 billion across 5 years, with a median of -$110.1 million in 2023.
- Annual changes were most pronounced in 2021 — Inventory Average tumbled 115.08% — and 2024, when it surged 1767.5%.
- Grifols' Inventory Average stood at -$163.9 million in 2021, then gained by 18.14% to -$134.1 million in 2022, then advanced by 17.95% to -$110.1 million in 2023, then surged by 1767.5% to $1.8 billion in 2024, then jumped by 108.15% to $3.8 billion in 2025.
- The last three Inventory Average figures came in at $3.8 billion (Q4 2025), $1.8 billion (Q4 2024), and -$110.1 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 8.09 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 14.14 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 14.39 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 5.00 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 6.57 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 6.21 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.84 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 10.66 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.72 Bn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - | 3.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.82 Bn |
| Dec 31, 2024 | 1.84 Bn |
| Dec 31, 2023 | -110.07 Mn |
| Dec 31, 2022 | -134.15 Mn |
| Dec 31, 2021 | -163.88 Mn |
| Dec 31, 2020 | 1.09 Bn |
| Sep 30, 2020 | 2.52 Bn |
| Mar 31, 2020 | 2.65 Bn |
| Dec 31, 2019 | 2.59 Bn |
| Sep 30, 2019 | 2.50 Bn |
| Mar 31, 2019 | 2.31 Bn |
| Dec 31, 2018 | 2.20 Bn |
| Sep 30, 2018 | 2.16 Bn |
| Jun 30, 2018 | 2.11 Bn |
| Mar 31, 2018 | 1.99 Bn |
| Dec 31, 2017 | 1.84 Bn |
| Dec 31, 2016 | 1.75 Bn |
| Sep 30, 2016 | 1.73 Bn |
| Dec 31, 2015 | 1.54 Bn |
| Mar 31, 2015 | 1.52 Bn |